Aethon Therapeutics
Creating neoantigens by design — to transform cancer treatments into cures.
- Employees
- 11–50
- Business Model
- B2B
- Website
- aethontx.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series AJan 2023
- Rounds
- 1
About
Aethon Therapeutics develops novel anti-drug-peptide conjugate/MHC antibodies using its proprietary HapImmune™ platform to fight drug-resistant cancers. The antibodies work in combination with targeted covalent inhibitors (TCIs) of RAS, EGFR, and other oncogenic mutations, enabling the immune system to recognize and eliminate residual cancer cells. The company was founded in 2022 by venture capital firm ATP and researchers from NYU Langone Health.
Summary
Aethon Therapeutics is a Biotech company. It has raised $30.0M in total across 1 round, most recently a $30.0M Series A round in Jan 2023. Investors include Apple Tree Partners.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jan 2023
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company